UniProt ID | ERBB2_HUMAN | |
---|---|---|
UniProt AC | P04626 | |
Protein Name | Receptor tyrosine-protein kinase erbB-2 | |
Gene Name | ERBB2 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 1255 | |
Subcellular Localization |
Isoform 1: Cell membrane Single-pass type I membrane protein. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1. Isoform 2: Cytoplasm. Nucl |
|
Protein Description | Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.; In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.. | |
Protein Sequence | MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
15 (in isoform 3) | Phosphorylation | - | 8.12 | 29116813 | |
68 | N-linked_Glycosylation | ELTYLPTNASLSFLQ EEEEECCCCCCHHHH | 26.12 | 20696930 | |
124 | N-linked_Glycosylation | LDNGDPLNNTTPVTG ECCCCCCCCCCCCCC | 49.54 | UniProtKB CARBOHYD | |
126 (in isoform 2) | Ubiquitination | - | 31.25 | - | |
127 | O-linked_Glycosylation | GDPLNNTTPVTGASP CCCCCCCCCCCCCCC | 20.20 | OGP | |
137 (in isoform 2) | Ubiquitination | - | 4.82 | - | |
150 | Ubiquitination | RSLTEILKGGVLIQR HHHHHHHHCCEEEEC | 60.32 | 21906983 | |
175 | Methylation | LWKDIFHKNNQLALT EHHHHHHHCCEEEEE | 47.01 | 412433599 | |
175 | Ubiquitination | LWKDIFHKNNQLALT EHHHHHHHCCEEEEE | 47.01 | 21890473 | |
182 | Phosphorylation | KNNQLALTLIDTNRS HCCEEEEEEEECCCC | 18.96 | 23403867 | |
187 | N-linked_Glycosylation | ALTLIDTNRSRACHP EEEEEECCCCCCCCC | 35.86 | UniProtKB CARBOHYD | |
196 | Phosphorylation | SRACHPCSPMCKGSR CCCCCCCCCCCCCCC | 21.81 | 27251275 | |
259 | N-linked_Glycosylation | CLACLHFNHSGICEL CEEECCCCCCCCEEE | 20.05 | 15093539 | |
530 | N-linked_Glycosylation | PGPTQCVNCSQFLRG CCCCCCCCHHHHHCC | 27.61 | 19299620 | |
571 | N-linked_Glycosylation | HPECQPQNGSVTCFG CCCCCCCCCCEEEEC | 51.93 | 20696930 | |
629 | N-linked_Glycosylation | ACQPCPINCTHSCVD CCCCCCCCCCCCCEE | 15.13 | UniProtKB CARBOHYD | |
686 | Phosphorylation | QQKIRKYTMRRLLQE HHHHHHHHHHHHHHH | 13.77 | 8702975 | |
694 | Phosphorylation | MRRLLQETELVEPLT HHHHHHHHCCCCCCC | 22.97 | 23403867 | |
701 | Phosphorylation | TELVEPLTPSGAMPN HCCCCCCCCCCCCCC | 26.56 | 27273156 | |
703 | Phosphorylation | LVEPLTPSGAMPNQA CCCCCCCCCCCCCHH | 33.67 | 28102081 | |
716 | Ubiquitination | QAQMRILKETELRKV HHHHHHHHHHHCCEE | 61.28 | - | |
724 | Ubiquitination | ETELRKVKVLGSGAF HHHCCEEEEECCCCC | 34.47 | - | |
728 | Phosphorylation | RKVKVLGSGAFGTVY CEEEEECCCCCCCEE | 23.84 | 21945579 | |
733 | Phosphorylation | LGSGAFGTVYKGIWI ECCCCCCCEEEEEEC | 17.76 | 21945579 | |
735 | Phosphorylation | SGAFGTVYKGIWIPD CCCCCCEEEEEECCC | 11.88 | 16729043 | |
736 | Ubiquitination | GAFGTVYKGIWIPDG CCCCCEEEEEECCCC | 39.31 | 21890473 | |
736 | Ubiquitination | GAFGTVYKGIWIPDG CCCCCEEEEEECCCC | 39.31 | 21890473 | |
747 | Ubiquitination | IPDGENVKIPVAIKV CCCCCCEEEEEEHHH | 53.53 | 21890473 | |
747 | Ubiquitination | IPDGENVKIPVAIKV CCCCCCEEEEEEHHH | 53.53 | 21890473 | |
753 | Ubiquitination | VKIPVAIKVLRENTS EEEEEEHHHHHCCCC | 26.02 | 21890473 | |
753 | Ubiquitination | VKIPVAIKVLRENTS EEEEEEHHHHHCCCC | 26.02 | 21890473 | |
759 | Phosphorylation | IKVLRENTSPKANKE HHHHHCCCCCHHCHH | 41.47 | 28102081 | |
760 | Phosphorylation | KVLRENTSPKANKEI HHHHCCCCCHHCHHH | 35.66 | 28102081 | |
772 | Phosphorylation | KEILDEAYVMAGVGS HHHHHHHHHHHCCCC | 6.68 | 28102081 | |
779 | Phosphorylation | YVMAGVGSPYVSRLL HHHHCCCCHHHHHHH | 15.62 | 28102081 | |
781 | Phosphorylation | MAGVGSPYVSRLLGI HHCCCCHHHHHHHHH | 16.86 | 28102081 | |
783 | Phosphorylation | GVGSPYVSRLLGICL CCCCHHHHHHHHHHH | 16.03 | 28102081 | |
819 | Phosphorylation | ENRGRLGSQDLLNWC HHCCCCCHHHHHHHH | 25.72 | 28102081 | |
854 | Ubiquitination | AARNVLVKSPNHVKI HHCCCEECCCCCEEE | 56.91 | - | |
860 | Ubiquitination | VKSPNHVKITDFGLA ECCCCCEEECCCCEE | 32.13 | 21890473 | |
860 | Ubiquitination | VKSPNHVKITDFGLA ECCCCCEEECCCCEE | 32.13 | 21890473 | |
875 | Phosphorylation | RLLDIDETEYHADGG EECCCCCCEEECCCC | 37.79 | 28152594 | |
876 | Phosphorylation | LLDIDETEYHADGGK ECCCCCCEEECCCCC | 33.02 | 17016520 | |
877 | Phosphorylation | LDIDETEYHADGGKV CCCCCCEEECCCCCC | 15.10 | 27273156 | |
883 | Ubiquitination | EYHADGGKVPIKWMA EEECCCCCCCCCHHH | 50.82 | - | |
887 | Ubiquitination | DGGKVPIKWMALESI CCCCCCCCHHHHHHH | 25.50 | 21890473 | |
900 | Phosphorylation | SILRRRFTHQSDVWS HHHHHCCCCHHHCHH | 19.73 | - | |
923 | Phosphorylation | MTFGAKPYDGIPARE HHCCCCCCCCCCHHH | 26.54 | 16729043 | |
937 | Ubiquitination | EIPDLLEKGERLPQP HCHHHHHCCCCCCCC | 67.07 | - | |
948 | Phosphorylation | LPQPPICTIDVYMIM CCCCCCEEEEEEEEE | 22.41 | - | |
952 | Phosphorylation | PICTIDVYMIMVKCW CCEEEEEEEEEHHHH | 4.16 | 16729043 | |
974 | Phosphorylation | PRFRELVSEFSRMAR HHHHHHHHHHHHHCC | 45.61 | 27251275 | |
977 | Phosphorylation | RELVSEFSRMARDPQ HHHHHHHHHHCCCCC | 19.66 | 27251275 | |
998 | Phosphorylation | NEDLGPASPLDSTFY CCCCCCCCCCCCHHH | 29.18 | 28355574 | |
1002 | Phosphorylation | GPASPLDSTFYRSLL CCCCCCCCHHHHHHC | 28.26 | 26356563 | |
1003 | Phosphorylation | PASPLDSTFYRSLLE CCCCCCCHHHHHHCC | 25.09 | 26356563 | |
1004 | Phosphorylation | ASPLDSTFYRSLLED CCCCCCHHHHHHCCC | 5.74 | 17016520 | |
1005 | Phosphorylation | SPLDSTFYRSLLEDD CCCCCHHHHHHCCCC | 10.20 | 16729043 | |
1007 | Phosphorylation | LDSTFYRSLLEDDDM CCCHHHHHHCCCCCC | 26.40 | 26356563 | |
1023 | Phosphorylation | DLVDAEEYLVPQQGF CCCCHHHHCCCCCCC | 12.42 | 16729043 | |
1049 | Phosphorylation | MVHHRHRSSSTRSGG CCEEECCCCCCCCCC | 23.63 | 25219547 | |
1050 | Phosphorylation | VHHRHRSSSTRSGGG CEEECCCCCCCCCCC | 35.37 | 21955146 | |
1051 | Phosphorylation | HHRHRSSSTRSGGGD EEECCCCCCCCCCCC | 29.14 | 21955146 | |
1052 | Phosphorylation | HRHRSSSTRSGGGDL EECCCCCCCCCCCCC | 30.70 | 25219547 | |
1054 | Phosphorylation | HRSSSTRSGGGDLTL CCCCCCCCCCCCCEE | 41.71 | 19664994 | |
1060 | Phosphorylation | RSGGGDLTLGLEPSE CCCCCCCEECCCCCC | 24.42 | 30266825 | |
1066 | Phosphorylation | LTLGLEPSEEEAPRS CEECCCCCCCCCCCC | 48.54 | 30266825 | |
1073 | Phosphorylation | SEEEAPRSPLAPSEG CCCCCCCCCCCCCCC | 24.17 | 30266825 | |
1078 | Phosphorylation | PRSPLAPSEGAGSDV CCCCCCCCCCCCCCC | 42.95 | 30266825 | |
1083 | Phosphorylation | APSEGAGSDVFDGDL CCCCCCCCCCCCCCC | 30.02 | 30266825 | |
1100 | Phosphorylation | GAAKGLQSLPTHDPS CCCCCHHHCCCCCCC | 41.16 | 30243723 | |
1103 | Phosphorylation | KGLQSLPTHDPSPLQ CCHHHCCCCCCCCCH | 44.17 | 30266825 | |
1107 | Phosphorylation | SLPTHDPSPLQRYSE HCCCCCCCCCHHCCC | 44.28 | 30266825 | |
1112 | Phosphorylation | DPSPLQRYSEDPTVP CCCCCHHCCCCCCCC | 11.94 | 20498373 | |
1113 | Phosphorylation | PSPLQRYSEDPTVPL CCCCHHCCCCCCCCC | 37.40 | 20639409 | |
1117 | Phosphorylation | QRYSEDPTVPLPSET HHCCCCCCCCCCCCC | 47.26 | 20639409 | |
1122 | Phosphorylation | DPTVPLPSETDGYVA CCCCCCCCCCCCCEE | 61.89 | 26356563 | |
1124 | Phosphorylation | TVPLPSETDGYVAPL CCCCCCCCCCCEECC | 38.78 | 26356563 | |
1126 | Phosphorylation | PLPSETDGYVAPLTC CCCCCCCCCEECCEE | 26.66 | 17016520 | |
1127 | Phosphorylation | LPSETDGYVAPLTCS CCCCCCCCEECCEEC | 9.03 | 27259358 | |
1132 | Phosphorylation | DGYVAPLTCSPQPEY CCCEECCEECCCCHH | 15.18 | 26356563 | |
1134 | Phosphorylation | YVAPLTCSPQPEYVN CEECCEECCCCHHCC | 22.72 | 26356563 | |
1139 | Phosphorylation | TCSPQPEYVNQPDVR EECCCCHHCCCCCCC | 16.04 | 16729043 | |
1151 | Phosphorylation | DVRPQPPSPREGPLP CCCCCCCCCCCCCCC | 43.18 | 27362937 | |
1166 | Phosphorylation | AARPAGATLERPKTL CCCCCCCCCCCCCCC | 28.38 | 30266825 | |
1172 | Phosphorylation | ATLERPKTLSPGKNG CCCCCCCCCCCCCCC | 34.84 | 26699800 | |
1174 | Phosphorylation | LERPKTLSPGKNGVV CCCCCCCCCCCCCCC | 36.52 | 28188228 | |
1196 | Phosphorylation | GAVENPEYLTPQGGA CCCCCCCCCCCCCCC | 19.68 | 16729043 | |
1198 | Phosphorylation | VENPEYLTPQGGAAP CCCCCCCCCCCCCCC | 16.80 | 27251275 | |
1214 | Phosphorylation | PHPPPAFSPAFDNLY CCCCCCCCCCCCCCE | 19.88 | - | |
1221 | Phosphorylation | SPAFDNLYYWDQDPP CCCCCCCEECCCCCC | 14.57 | 15695410 | |
1222 | Phosphorylation | PAFDNLYYWDQDPPE CCCCCCEECCCCCCC | 12.99 | 16729043 | |
1235 | Phosphorylation | PERGAPPSTFKGTPT CCCCCCCCCCCCCCC | 45.47 | 26356563 | |
1236 | Phosphorylation | ERGAPPSTFKGTPTA CCCCCCCCCCCCCCC | 34.83 | 26356563 | |
1240 | Phosphorylation | PPSTFKGTPTAENPE CCCCCCCCCCCCCCC | 20.32 | 26356563 | |
1242 | Phosphorylation | STFKGTPTAENPEYL CCCCCCCCCCCCCCC | 46.58 | 26356563 | |
1247 | Phosphorylation | TPTAENPEYLGLDVP CCCCCCCCCCCCCCC | 66.04 | 17016520 | |
1248 | Phosphorylation | PTAENPEYLGLDVPV CCCCCCCCCCCCCCC | 13.81 | 16794579 | |
1248 | Dephosphorylation | PTAENPEYLGLDVPV CCCCCCCCCCCCCCC | 13.81 | 11067847 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
686 | T | Phosphorylation | Kinase | PRKACA | P17612 | GPS |
686 | T | Phosphorylation | Kinase | PKA-FAMILY | - | GPS |
686 | T | Phosphorylation | Kinase | PKCA | P05696 | PSP |
686 | T | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
686 | T | Phosphorylation | Kinase | PRKG2 | Q13237 | GPS |
701 | T | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
701 | T | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
877 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | GPS |
877 | Y | Phosphorylation | Kinase | FYN | P06241 | PSP |
877 | Y | Phosphorylation | Kinase | SRC | P12931 | PSP |
877 | Y | Phosphorylation | Kinase | YES | P07947 | PSP |
900 | T | Phosphorylation | Kinase | PRKAA1 | Q13131 | GPS |
1023 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | GPS |
1112 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | GPS |
1139 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | PhosphoELM |
1172 | T | Phosphorylation | Kinase | KCC2A | Q9UQM7 | PhosphoELM |
1172 | T | Phosphorylation | Kinase | CAMK2A | P11275 | PSP |
1196 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | PhosphoELM |
1221 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | PhosphoELM |
1222 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | PhosphoELM |
1248 | Y | Phosphorylation | Kinase | ERBB2 | P04626 | PhosphoELM |
- | K | Ubiquitination | E3 ubiquitin ligase | STUB1 | Q9UNE7 | PMID:12239347 |
- | K | Ubiquitination | E3 ubiquitin ligase | CBL | P22681 | PMID:10910043 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ERBB2_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ERBB2_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
H00018 | Gastric cancer | |||||
H00019 | Pancreatic cancer | |||||
H00022 | Bladder cancer | |||||
H00026 | Endometrial Cancer | |||||
H00027 | Ovarian cancer | |||||
H00028 | Choriocarcinoma | |||||
H00030 | Cervical cancer | |||||
H00031 | Breast cancer | |||||
H00046 | Cholangiocarcinoma | |||||
OMIM Disease | ||||||
137215 | Hereditary diffuse gastric cancer (HDGC) | |||||
137800 | Glioma (GLM) | |||||
167000 | Ovarian cancer (OC) | |||||
211980 | Lung cancer (LNCR) | |||||
613659 | Gastric cancer (GASC) | |||||
Kegg Drug | ||||||
D02714 | Everolimus (JAN/USAN/INN); Afinitor (TN); Votubia (TN); Zortress (TN) | |||||
D03257 | Trastuzumab (genetical recombination) (JAN); Trastuzumab (INN); Herceptin (TN) | |||||
D03350 | Canertinib dihydrochloride (USAN) | |||||
D04024 | Lapatinib tosilate hydrate (JAN); Lapatinib ditosylate (USAN); Tykerb (TN) | |||||
D04025 | Mubritinib (USAN/INN) | |||||
D05446 | Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN); Perjeta (TN) | |||||
D08108 | Lapatinib (INN) | |||||
D08950 | Neratinib (INN/USAN) | |||||
D09689 | Varlitinib (USAN/INN) | |||||
D09690 | Varlitinib tosylate (USAN) | |||||
D09724 | Afatinib (USAN/INN) | |||||
D09733 | Afatinib maleate (JAN); Afatinib dimaleate (USAN) | |||||
D09883 | Dacomitinib (USAN/INN) | |||||
D09980 | Trastuzumab emtansine (genetical recombination) (JAN); Trastuzumab emtansine (USAN/INN); Kadcyla (TN | |||||
D10344 | Nelipepimut-S (USAN); Neuvax | |||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
N-linked Glycosylation | |
Reference | PubMed |
"Structural basis for high-affinity HER2 receptor binding by anengineered protein."; Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITHENGINEERED ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION ATASN-68; ASN-259 AND ASN-571. | |
"Variants of the antibody herceptin that interact with HER2 and VEGFat the antigen binding site."; Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K.,Man W., Peale F., Ross S., Wiesmann C., Fuh G.; Science 323:1610-1614(2009). Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THEANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 ANDASN-530. | |
"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex."; Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M.,Sliwkowski M.X.; Cancer Cell 5:317-328(2004). Cited for: X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THEANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187;ASN-259 AND ASN-530. | |
Phosphorylation | |
Reference | PubMed |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND MASSSPECTROMETRY. | |
"Multiple reaction monitoring for robust quantitative proteomicanalysis of cellular signaling networks."; Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.; Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND MASSSPECTROMETRY. | |
"Plexin-B2, but not Plexin-B1, critically modulates neuronal migrationand patterning of the developing nervous system in vivo."; Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A.,Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L.,Offermanns S., Kuner R.; J. Neurosci. 27:6333-6347(2007). Cited for: PHOSPHORYLATION AT TYR-1248. | |
"Global survey of phosphotyrosine signaling identifies oncogenickinases in lung cancer."; Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.; Cell 131:1190-1203(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-735, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND MASSSPECTROMETRY. |